Abbott Laboratories
ABT · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $13,402,000 | $5,723,000 | $6,933,000 | $7,071,000 |
| Dep. & Amort. | $3,218,000 | $3,243,000 | $3,267,000 | $3,538,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $673,000 | $644,000 | $685,000 | $640,000 |
| Change in WC | -$9,217,000 | -$2,475,000 | -$1,519,000 | -$771,000 |
| Other Non-Cash | $482,000 | $126,000 | $215,000 | $55,000 |
| Operating Cash Flow | $8,558,000 | $7,261,000 | $9,581,000 | $10,533,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$2,207,000 | -$2,202,000 | -$1,777,000 | -$1,885,000 |
| Net Acquisitions | $1,000 | -$837,000 | $48,000 | -$53,000 |
| Inv. Purchases | -$169,000 | -$159,000 | -$185,000 | -$173,000 |
| Inv. Sales/Matur. | $28,000 | $43,000 | $152,000 | $77,000 |
| Other Inv. Act. | $9,000 | $22,000 | $22,000 | $26,000 |
| Investing Cash Flow | -$2,338,000 | -$3,133,000 | -$1,740,000 | -$2,008,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$537,000 | -$2,475,000 | -$699,000 | -$248,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$1,295,000 | -$1,227,000 | -$3,795,000 | -$2,299,000 |
| Dividends Paid | -$3,836,000 | -$3,556,000 | -$3,309,000 | -$3,202,000 |
| Other Fin. Act. | $264,000 | $167,000 | $167,000 | $255,000 |
| Financing Cash Flow | -$5,404,000 | -$7,091,000 | -$7,636,000 | -$5,494,000 |
| Forex Effect | -$96,000 | -$23,000 | -$122,000 | -$70,000 |
| Net Chg. in Cash | $720,000 | -$2,986,000 | $83,000 | $2,961,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $6,896,000 | $9,882,000 | $9,799,000 | $6,838,000 |
| End Cash | $7,616,000 | $6,896,000 | $9,882,000 | $9,799,000 |
| Free Cash Flow | $6,351,000 | $5,059,000 | $7,804,000 | $8,648,000 |